Pfizer refiles Seagen acquisition paperwork, deal still expected to close within the year

Jaimy Lee

Deputy Editor

Pfizer’s decision to refile the paperwork for its $43 billion acquisition of Seagen likely allows the drugmaker to provide more information about the deal to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer refiles Seagen acquisition paperwork, deal still expected to close within the year

Jaimy Lee

Deputy Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Pfiz­er re­files Seagen ac­qui­si­tion pa­per­work, deal still ex­pect­ed to close with­in the year

Deputy Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Pfizer refiles Seagen acquisition paperwork, deal still expected to close within the year